Atlas Trials

Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Clinical trial NCT07171827 · COMPLETED

Trial details

NCT number
NCT07171827
Sponsor
Helwan University
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Anti-CD30BrentuximabDoxorubicinVinblastineDacarbazineFrontlineAdvanced Classical Hodgkin Lymphoma
Start date
2023-03-01
Primary completion
2025-02-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.